Efficacy News and Research

RSS
Discovery of cancer drugs to kill malaria parasite could open up new strategies for treatment

Discovery of cancer drugs to kill malaria parasite could open up new strategies for treatment

Thought leaders gather to examine challenges facing patients with primary immunodeficiencies

Thought leaders gather to examine challenges facing patients with primary immunodeficiencies

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

Repligen anticipates 30% increase in total revenues for 2011

Repligen anticipates 30% increase in total revenues for 2011

Baxter’s first quarter global sales increase 12% to $3.3 billion

Baxter’s first quarter global sales increase 12% to $3.3 billion

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Stanford and SanBio initiate SB623 Phase 1/2a clinical trial for stroke disability

Stanford and SanBio initiate SB623 Phase 1/2a clinical trial for stroke disability

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

Ludwig Institute demonstrates ability of DAVANAT to enhance efficacy of T-lymphocytes to kill tumor cells

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Study shows possibility of women living with AIDS to breastfeed with lower risk

Study shows possibility of women living with AIDS to breastfeed with lower risk

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Rituxan receives FDA approval for treating two rare diseases

Rituxan receives FDA approval for treating two rare diseases

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

African AIDS drug trial stopped prematurely

African AIDS drug trial stopped prematurely

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction

NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.